preclin
therapeut
develop
research
direct
toward
fulfil
two
overlap
set
goal
set
scientif
goal
includ
defin
best
molecul
biolog
construct
task
hand
prove
case
develop
second
set
goal
address
regulatori
requir
necessari
introduc
agent
human
subject
case
small
molecul
drug
case
ident
molecul
appropri
safeti
studi
straightforward
contrast
develop
biolog
agent
includ
gene
therapi
discuss
present
distinct
challeng
natur
drug
may
organ
subject
mutat
select
variant
recombin
properti
may
vari
depend
scale
method
prepar
purif
storag
test
adequ
safeti
prior
first
introduct
human
may
straightforward
owe
intrins
differ
respons
agent
expect
human
compar
anim
gener
principl
howev
allow
firstinhuman
experi
similar
small
molecul
biolog
ethic
conduct
clinic
trial
patient
dire
lifethreaten
diseas
demand
understand
ident
dose
agent
possibl
caus
clinic
benefit
advers
event
expect
worst
easili
revers
well
predict
preclin
experi
normal
volunt
patient
otherwis
well
evid
gather
would
support
initi
rang
dose
test
agent
expect
without
substanti
toxic
longterm
effect
thu
success
clinic
introduct
novel
therapeut
concept
requir
organ
approach
integr
scientif
technic
regulatori
requir
integr
begin
research
laboratori
concept
becom
candid
clinic
prevent
avoid
expens
delay
clinic
develop
exampl
product
creat
use
mammalian
cell
line
viral
contamin
rule
costli
rederiv
requir
product
manufactur
clinic
trial
use
current
good
manufactur
practic
cgmp
hand
discoveri
phase
excess
prematur
concern
cgmp
complianc
imped
research
therefor
clear
strateg
understand
principl
underli
regulatori
issu
desir
goal
chapter
proceed
experi
development
therapeut
program
dtp
nation
cancer
institut
manufactur
biolog
includ
gene
therapi
construct
preclin
clinic
use
outlin
basi
approach
safeti
test
studi
includ
investig
new
drug
ind
applic
food
drug
administr
fda
focu
studi
would
allow
phase
perhap
earli
phase
ii
clinic
trial
dtp
contribut
differ
cgmp
biolog
project
activ
select
competit
applic
receiv
academ
research
intramur
laboratori
nation
institut
health
nih
dtp
product
includ
virus
vaccin
gene
therapi
plasmid
monoclon
antibodi
recombin
protein
synthet
peptid
natur
product
ferment
oligonucleotid
fiscal
year
differ
lot
manufactur
releas
cgmp
clinic
use
cgmp
manufactur
product
destin
phase
phase
ii
clinic
trial
cancer
beyond
earli
phase
iii
clinic
trial
technolog
transfer
product
occur
develop
phase
iii
address
pharmaceut
compani
base
experi
accumul
sever
year
abstract
initi
profil
success
concept
tabl
well
earli
project
characterist
imped
clinic
develop
tabl
note
correl
thorough
earli
research
attent
rule
outlin
refer
cite
develop
commerci
interest
product
gene
therapi
biolog
therapeut
regul
within
fda
center
biolog
evalu
research
cber
creat
address
product
emerg
new
biotechnolog
reorgan
fda
current
way
result
regul
mani
biotherapeut
center
drug
evalu
research
oversight
small
molecul
drug
anticip
howev
blood
product
vaccin
gene
therapi
product
remain
cber
biolog
respons
modifi
advisori
committe
charter
advisori
group
role
advis
fda
ensur
safeti
effect
biolog
product
includ
gene
therapi
recombin
dna
advisori
committe
rac
also
overse
gene
therapi
research
nih
offic
biotechnolog
activ
rac
establish
respons
public
concern
regard
safeti
recombin
deoxyribonucl
acid
dna
technolog
human
gene
transfer
trial
nih
fund
involv
either
directli
indirectli
submit
rac
review
tabl
beyond
good
idea
success
investig
alreadi
done
project
lead
commerci
develop
defin
candid
biolog
molecul
made
comparison
similar
product
characterist
product
consist
pharmaceut
requir
product
scale
adequ
product
character
adequ
laboratori
refer
standard
exist
vitro
potenc
assay
develop
stabil
studi
develop
confid
product
drug
reproduc
model
system
confirm
vivo
activ
clinic
product
earli
anim
work
includ
toxicolog
scaleup
requir
practic
initi
clinic
trial
gener
reflect
experi
scientif
matur
investig
addit
us
agenc
develop
regul
govern
drug
develop
licens
intern
confer
harmon
ich
form
april
involv
unit
state
european
union
japan
address
issu
global
regul
ich
steer
committe
meet
least
twice
year
continu
agenda
updat
harmon
regul
medicin
product
emphas
safeti
qualiti
efficaci
expert
work
group
form
within
ich
address
specif
topic
relat
basic
area
although
fda
formal
adopt
ich
guidelin
guidelin
follow
exist
preliminari
form
investig
plan
conduct
investig
drug
trial
foreign
countri
imper
familiar
adher
regul
set
forth
ich
seri
fda
ich
guidanc
document
character
preclin
safeti
evalu
biotechnologyderiv
pharmaceut
develop
guidanc
repres
fda
current
think
preclin
safeti
evalu
biotechnologyderiv
pharmaceut
defin
product
deriv
character
cell
use
varieti
express
system
includ
bacteria
yeast
insect
plant
mammalian
cell
activ
substanc
may
includ
protein
peptid
deriv
product
compon
materi
could
deriv
cell
cultur
produc
use
recombin
dna
technolog
includ
product
transgen
plant
anim
exampl
includ
cytokin
enzym
fusion
protein
growth
factor
hormon
monoclon
antibodi
plasminogen
activ
recombin
plasma
factor
receptor
intend
indic
use
human
may
includ
vivo
diagnost
therapeut
prophylact
use
principl
outlin
guidanc
document
may
also
applic
recombin
dna
protein
vaccin
chemic
synthes
peptid
plasmaderiv
product
endogen
protein
extract
human
tissu
oligonucleotid
drug
fda
defin
gene
therapi
medic
intervent
base
modif
genet
materi
live
cell
cell
may
modifi
ex
vivo
subsequ
administr
human
may
alter
vivo
gene
therapi
given
directli
patient
genet
manipul
perform
ex
vivo
cell
administ
patient
also
consid
form
somat
cell
therapi
genet
manipul
may
intend
therapeut
prophylact
tabl
issu
requir
attent
outset
project
inappropri
antibiot
select
marker
eg
ampicillin
recombin
protein
labscal
affin
purif
solubl
problem
low
yield
error
genet
sequenc
extran
genet
materi
poorli
defin
product
system
inadequ
purif
scheme
unvalid
nonexist
vitro
potenc
assay
lack
key
reagent
eg
antibodi
desir
product
poor
biochem
character
inappropri
raw
materi
raw
materi
qualif
problem
inappropri
cell
bank
difficult
unidentifi
toxicolog
system
fail
vendor
qualif
intellectu
properti
concern
effect
may
provid
way
mark
cell
later
identif
recombin
dna
materi
use
transfer
genet
materi
therapi
consid
compon
gene
therapi
subject
regulatori
oversight
specif
inform
relat
gene
therapi
issu
contain
fda
guidanc
industri
guidanc
human
somat
cell
therapi
gene
therapi
guidanc
document
updat
replac
fda
point
consid
subject
new
inform
intend
provid
manufactur
current
inform
regard
regulatori
concern
product
qualiti
control
test
administr
recombin
vector
gene
therapi
preclin
test
cellular
therapi
vector
fda
defin
somat
cell
therapi
administr
human
autolog
allogen
xenogen
live
nongermlin
cell
transfus
blood
product
therapeut
diagnost
prevent
purpos
evalu
safeti
gene
therapi
product
perhap
one
difficult
task
face
toxicologist
drug
develop
arena
today
mani
agent
like
biolog
speci
specif
agent
integr
host
genom
choic
anim
model
studi
design
fraught
uncertainti
product
frequent
break
new
regulatori
ground
recent
mani
investig
work
field
probabl
lull
fals
sens
secur
close
scrutini
preclin
studi
clinic
protocol
receiv
nih
rac
fda
death
jess
gelsing
patient
enrol
gene
therapi
clinic
trial
correct
metabol
diseas
recent
report
leukemialik
diseas
produc
children
receiv
gene
therapi
treatment
correct
sever
combin
immunodefici
diseas
scid
safeti
agent
call
question
ever
result
toxicologist
even
pressur
design
rigor
safeti
evalu
program
number
review
area
recent
year
toxicologist
fda
industri
intern
workshop
cover
mani
fundament
regard
safeti
evalu
gene
therapi
product
resourc
conjunct
chapter
variou
guidanc
document
fda
ich
use
toxicologist
develop
sound
safeti
program
issu
discuss
greater
detail
latter
half
chapter
basic
foundat
regul
drug
develop
found
code
feder
regul
titl
food
drug
cfr
addit
titl
fda
maintain
extens
number
web
site
contain
regulatori
inform
consult
develop
novel
biotherapeut
collect
avail
regulatori
inform
includ
point
consid
guidanc
document
draft
report
public
forum
symposia
well
inform
meet
biolog
respons
modifi
advisori
committe
ich
also
sponsor
web
site
obtain
recent
guidelin
free
subscript
email
advisori
updat
servic
also
avail
tabl
addit
regulatori
guidelin
provid
fda
nih
publish
frequent
updat
nih
guidelin
research
involv
recombin
dna
molecul
also
found
electron
tabl
although
publish
document
dissemin
fda
nih
essenti
start
point
plan
cgmp
develop
strategi
import
realiz
rapidli
evolv
field
requir
may
reflect
public
comment
grow
consensu
among
industri
long
formal
adopt
furthermor
unusu
develop
new
biolog
also
develop
altern
convent
practic
base
sound
scientif
data
implement
discuss
fda
productspecif
factor
influenc
regulatori
requir
investig
agent
issu
explor
detail
fda
preind
meet
ind
sponsor
present
relev
preclin
data
manufactur
anim
safeti
test
support
propos
approach
clinic
develop
type
studi
pertin
particular
agent
propos
input
agenc
help
shape
final
develop
plan
interact
take
place
regulatori
author
interv
facilit
develop
product
tabl
key
issu
frequent
understood
regulatori
demand
becom
stringent
product
move
phase
safeti
phase
ii
activ
phase
iii
compar
efficaci
trial
licensur
philosophi
reflect
consciou
effort
stifl
innov
earli
phase
clinic
test
ensur
time
registrationori
latestag
trial
contempl
issu
relat
product
variabl
assay
assur
safeti
matur
wellsubstanti
result
trial
could
basi
sale
agent
public
anoth
factor
affect
level
regulatori
complianc
natur
studi
popul
product
manufactur
phase
trial
healthi
normal
volunt
typic
must
meet
much
stricter
requir
studi
patient
dire
lifethreaten
condit
eg
cancer
endstag
acquir
immunodefici
syndrom
improv
technolog
becom
avail
requir
also
tend
increas
level
regulatori
complianc
follow
differ
stage
develop
depend
type
biolog
product
technolog
avail
support
develop
assay
method
technolog
monoclon
antibodi
develop
instanc
better
defin
techniqu
avail
new
viru
vector
emerg
furthermor
new
technolog
support
product
develop
also
constantli
evolv
number
specif
viral
contamin
test
requir
cgmp
human
cell
line
exampl
increas
steadili
new
pathogen
identifi
assay
becom
avail
new
scientif
knowledg
accumul
novel
regulatori
challeng
appear
issu
transmiss
spongiform
encephalopathi
exampl
result
stringent
requir
raw
materi
qualif
traceabl
minim
impact
regulatori
chang
care
record
keep
process
materi
involv
deriv
product
highli
recommend
final
avail
improv
techniqu
character
certain
biolog
fda
reorgan
regulatori
approach
way
analog
regul
small
molecul
drug
technic
demand
rise
regulatori
requir
becom
standard
beyond
identif
confirm
interest
novel
concept
major
challeng
preclin
develop
biolog
optim
alloc
research
develop
resourc
key
proper
assess
candid
concept
readi
clinic
develop
applic
nation
cancer
institut
biolog
product
resourc
receiv
list
gener
question
correspond
appropri
product
type
begin
project
alway
reason
expect
issu
resolv
assumpt
success
candid
issu
hand
time
project
complet
phase
clinic
test
tabl
list
gener
question
cgmp
product
recombin
viru
vector
possibl
provid
complet
guid
cgmp
develop
page
highlight
concern
common
mani
project
aris
academ
laboratori
base
dtp
experi
success
failur
project
make
transit
preclin
research
phase
pilot
clinic
studi
discuss
organ
primarili
around
concept
ident
puriti
potenc
safeti
underli
develop
manufactur
releas
viewpoint
regulatori
complianc
essenti
establish
ident
product
compon
use
gener
manufactur
note
frequent
propos
gene
therapi
recombin
dnaderiv
product
submit
us
dna
sequenc
show
deviat
sequenc
publish
andor
submit
investig
sometim
major
consequ
project
dna
product
plasmid
vaccin
administ
patient
full
plasmid
sequenc
occasion
reveal
unaccept
genet
sequenc
outsid
open
read
frame
passeng
previou
experi
spuriou
promot
frame
shift
result
translat
nonsens
sequenc
beyond
intend
termin
dna
sequenc
repair
avail
rel
low
cost
compar
cost
repeat
critic
preclin
experi
fda
requir
complet
sequenc
vector
size
kilobas
kb
viral
vector
genet
stabil
major
concern
particularli
respect
possibl
issu
recombin
gener
replicationcompet
virus
specif
guidelin
provid
adenoviru
retroviru
lentiviru
vector
viru
vector
specif
assay
eg
neurovirul
test
recombin
polioviru
herp
viru
vector
requir
ensur
attenu
phenotyp
preserv
scaleup
possibl
investig
attempt
assess
genet
stabil
vector
preclin
studi
administr
vivo
propag
vitro
addit
gene
therapi
product
cell
use
produc
product
must
similarli
identifi
qualifi
cgmp
manufactur
excel
guidanc
document
avail
product
master
cell
bank
work
cell
bank
master
viru
bank
minimum
complet
cell
histori
known
document
cell
test
verifi
origin
peptid
sequenc
map
employ
liquid
chromatographymass
spectrometri
typic
use
provid
critic
inform
synthet
peptid
recombin
protein
recombin
vector
contain
transgen
express
desir
gene
product
verifi
exampl
immunoassay
use
specif
antibodi
product
nongmp
addit
preclin
develop
b
cgmp
clinic
grade
provid
detail
molecular
construct
includ
start
materi
eg
plasmid
relev
vector
map
detail
vector
construct
scheme
construct
contain
antibiot
resist
gene
select
marker
altern
method
select
avail
propos
select
chosen
vector
replic
compet
replic
defect
replicationselect
vector
molecular
basi
select
condit
vector
would
replic
vector
alter
cell
tropism
defin
effect
alter
tropism
anticip
host
toxic
construct
sequenc
provid
sequenc
electron
format
data
avail
evalu
genet
stabil
recombin
vector
mutat
rate
establish
andor
rate
revers
either
wildtyp
altern
viral
genom
data
avail
evalu
potenti
genet
recombin
organ
patient
environ
organ
current
grown
qualifi
cgmp
cell
line
qualifi
cell
line
avail
propag
vector
cell
line
genet
modifi
support
vector
provid
detail
construct
inform
regard
stabil
genet
alter
cell
line
cgmpqualifi
viru
seed
bank
provid
detail
propos
product
method
materi
ever
produc
laboratori
clinic
studi
use
product
system
materi
produc
relat
product
system
pleas
provid
detail
pleas
provid
detail
exist
purif
method
averag
yield
product
system
purif
largest
amount
materi
produc
laboratori
singl
product
batch
pleas
provid
averag
ratio
obtain
product
method
viru
particleinfecti
unit
infecti
unitscel
scale
anticip
quantiti
clinic
trial
much
materi
avail
refer
standard
materi
avail
bulk
biolog
substanc
preliminari
pharmacolog
toxicolog
studi
reproduc
assay
product
pleas
provid
follow
assay
avail
ident
b
puriti
c
potenc
releas
criteria
product
one
know
lot
product
qualifi
use
form
lyophil
formul
product
fill
size
desir
final
product
desir
final
product
formul
issu
formul
must
resolv
known
product
stabil
respect
physic
integr
activ
inform
regard
estim
cost
product
project
identifi
possibl
sourc
product
commerci
firm
pleas
provid
detail
safeti
issu
connect
product
purif
andor
handl
product
statu
product
regard
intellectu
properti
issu
sometim
propos
project
improv
modif
exist
approach
case
inform
may
significantli
affect
analysi
feasibl
cost
product
issu
pleas
provid
brief
summari
natur
anteced
approach
appear
close
relat
propos
project
meet
schedul
regulatori
agenc
preind
meet
fda
present
nih
rac
pleas
indic
type
meet
regulatori
agenc
date
propos
date
preind
rac
meet
issu
concern
manufactur
safeti
stabil
rais
impact
produc
product
sponsor
ind
propos
studi
sourc
fund
identifi
perform
clinic
trial
product
purif
strategi
depend
natur
biolog
agent
expect
impur
approach
guid
earli
develop
reliabl
analyt
techniqu
appropri
product
manufactur
approach
exampl
purif
recombin
protein
monoclon
antibodi
cgmp
manufactur
typic
involv
largescal
chromatographi
base
multipl
isol
principl
eg
charg
hydrophob
size
specif
contamin
dna
endotoxin
virus
mammalian
cell
product
system
contamin
introduc
manufactur
process
like
must
quantifi
may
requir
addit
specif
purif
measur
remov
inactiv
problem
refold
solubl
tendenc
aggreg
product
stabil
intermedi
hold
point
signific
issu
process
develop
scaleup
repres
key
challeng
scaleup
investig
laboratorygener
lot
potenti
suitabl
scale
allow
clinic
test
addit
concern
includ
subtl
degrad
protein
lead
undesir
immunogen
major
concern
impact
addit
step
downstream
product
reassess
use
vitro
potenc
assay
well
physicochem
character
major
develop
mileston
select
vivo
model
reexamin
use
purifi
product
product
cell
must
cgmp
qualifi
test
adventiti
agent
contamin
initi
product
well
end
product
number
cgmpqualifi
cell
line
start
vector
avail
commerci
rel
low
cost
consid
use
raw
materi
initi
cgmp
seed
bank
prefer
share
materi
uncertain
proven
despit
good
intent
origin
provid
handl
cell
line
care
also
taken
avoid
contamin
eg
media
compon
trypsin
activ
take
place
nearbi
laboratori
space
postproduct
cell
test
specif
contamin
presenc
viral
product
eg
use
polymeras
chain
reaction
pcr
presenc
viru
product
howev
unlik
full
set
cgmp
test
eg
cocultiv
adventiti
agent
perform
postproduct
cell
initi
cgmp
product
therefor
investig
consid
parallel
propag
mockinfect
control
provid
surrog
postproduct
test
articl
addit
usual
test
steril
puriti
purifi
investig
product
import
assay
residu
host
cell
dna
assay
host
cell
protein
alway
requir
phase
product
requir
phase
ii
beyond
consider
anoth
reason
start
cgmpqualifi
cell
line
commerci
sourc
host
cell
dna
protein
assay
may
alreadi
avail
gener
requir
adventiti
agent
test
given
guidanc
document
eg
ref
import
note
specif
assay
yet
describ
publish
fda
document
enter
widespread
cgmp
practic
sponsorbas
industri
consensu
liabil
consider
factor
endotoxin
assay
avail
kit
use
guid
laboratori
process
develop
qualifi
good
laboratori
practic
glp
laboratori
howev
perform
endotoxin
assay
clinic
product
releas
specif
assay
may
also
requir
quantifi
process
residu
product
purif
compon
cscl
antibiot
product
facil
particularli
differ
type
gene
therapi
product
may
produc
assay
necessari
support
decontamin
clean
product
changeov
environment
monitor
raw
materi
qualif
gener
equip
contact
investig
product
verifi
free
contamin
use
special
consider
must
also
given
assay
qualifi
viru
seed
end
product
presenc
defect
particl
replicationcompet
virus
defect
genom
addit
monitor
replicationcompet
andor
pathogen
vector
manufactur
suitabl
assay
may
also
requir
monitor
patient
receiv
therapeut
agent
case
level
sensit
detect
must
suitabl
differ
type
patient
specimen
serum
urin
sputum
evolv
requir
longterm
followup
gene
therapi
patient
consult
ensur
proper
assay
support
maintain
beyond
durat
plan
clinic
trial
fda
regul
govern
perform
assay
support
product
biolog
human
use
found
cfr
subpart
laboratori
control
glp
regul
pertain
perform
preclin
anim
vitro
studi
measur
activ
biolog
candid
depend
hypothes
molecular
mechan
therapeut
action
cfr
although
reassur
see
vivo
demonstr
efficaci
appropri
anim
model
effici
develop
cgmp
process
strongli
benefit
avail
rapid
reliabl
reproduc
vitro
assay
relat
mechan
action
addit
assay
puriti
ident
assay
base
basic
therapeut
mechan
therefor
critic
goal
earli
research
develop
formul
develop
begin
earli
possibl
suitabl
assay
becom
avail
experi
realtim
stabil
accumul
prefer
choos
formul
candid
like
accept
fda
whose
compon
alreadi
use
licens
product
product
reach
larger
scale
handl
storag
consider
becom
increasingli
import
stabil
studi
incorpor
assay
ident
puriti
includ
aggreg
potenc
although
provid
use
inform
acceler
stabil
studi
typic
reliabl
predict
realtim
stabil
biolog
therefor
need
realtim
stabil
studi
initi
soon
possibl
suitabl
formul
product
also
assess
ident
administr
handl
condit
expect
clinic
may
includ
transient
exposur
condit
expect
transit
studi
site
storag
environ
close
mimic
studi
site
condit
may
result
markedli
differ
product
behavior
studi
site
expect
behavior
voucher
specimen
central
repositori
site
result
ongo
stabil
studi
use
support
process
develop
evalu
product
intermedi
hold
point
scaleup
product
product
releas
support
formul
develop
product
storag
shipment
handl
toxicolog
studi
clinic
applic
develop
proce
master
specif
releas
intermedi
final
product
establish
refin
ind
must
indic
schedul
realtim
stabil
studi
perform
throughout
durat
clinic
trial
key
earli
mileston
common
product
area
includ
attain
adequ
scale
highqual
singlebatch
product
avail
adequ
amount
highqual
laboratori
refer
standard
develop
reliabl
assay
ident
puriti
potenc
product
mileston
necessari
addit
explor
anim
model
show
safeti
promis
evid
efficaci
earli
stage
project
investig
expect
substanti
variabl
product
qualiti
assay
anim
model
ideal
therefor
singl
highqual
batch
use
establish
laboratori
standard
support
multipl
assay
qualif
run
perform
replic
anim
model
experi
multipl
product
run
could
perform
explor
process
develop
issu
includ
scaleup
way
fundament
issu
could
explor
research
stage
prepar
develop
requir
cgmp
manufactur
follow
reason
facil
often
manufactur
highqual
glp
lot
provid
uniform
suppli
materi
addit
preclin
research
develop
select
biolog
interest
make
decis
undertak
cgmp
product
earli
establish
certain
aspect
glp
cfr
crucial
advanc
drug
develop
project
follow
simpl
rule
laboratori
cleanli
document
segreg
materi
activ
start
develop
time
save
avoid
necess
duplic
result
properli
perform
document
outset
discoveri
phase
develop
reliabl
assay
explor
basic
therapeut
mechan
action
import
perform
anim
model
lay
groundwork
futur
cgmp
product
develop
laboratori
facil
staff
adequ
perform
necessari
studi
assay
protocol
specif
reproduc
research
document
kept
glp
level
complet
secur
laboratori
notebook
record
reagent
ie
manufactur
catalog
number
lot
number
certif
analysi
coa
expir
date
routin
archiv
even
cgmp
product
test
contempl
develop
laboratori
fluctuat
product
activ
unusu
later
scaleup
materi
inform
may
use
resolv
issu
key
assay
product
reagent
ident
repeat
appropri
interv
access
critic
raw
materi
reagent
refer
standard
cell
bank
limit
staff
avoid
comingl
researchgrad
glp
gmp
activ
reagent
label
reagent
contain
sequest
much
possibl
similarli
sign
post
dedic
equip
access
limit
appropri
common
equip
must
use
standard
oper
procedur
develop
defin
use
control
equip
clean
equip
use
avoid
crosscontamin
document
use
clean
calibr
equip
critic
raw
materi
eg
use
seed
develop
pilot
product
manufactur
must
traceabl
sourc
obtain
reliabl
vendor
benefici
possibl
use
vendor
subject
commerci
audit
animalderiv
reagent
avoid
reagent
glycerol
deterg
protein
amino
acid
like
prefer
come
veget
sourc
possibl
animalderiv
reagent
come
accept
herd
countri
without
endem
question
transmiss
spongiform
encephalopathi
import
ensur
raw
materi
store
appropri
condit
use
beyond
expir
date
inventori
logbook
use
track
use
import
reagent
critic
materi
requir
special
storag
condit
store
one
locat
prevent
loss
event
equip
failur
cgmpqualifi
cell
line
purchas
vendor
possibl
cgmpqualifi
cell
line
exist
cell
line
obtain
directli
reliabl
repositori
sourc
american
type
cultur
collect
atcc
document
archiv
incom
cell
line
must
test
steril
mycoplasma
contamin
thorough
record
kept
cell
passag
observ
frozen
storag
coa
media
compon
use
grow
freez
otherwis
manipul
cell
critic
cell
line
segreg
prevent
crosscontamin
stock
cell
cultur
incub
contain
virusinfect
cell
line
vector
purchas
reliabl
vendor
document
kept
propag
storag
use
includ
coa
lot
number
reagent
use
propag
vector
vector
acquir
anoth
laboratori
ie
unavail
purchas
vendor
detail
histori
obtain
gener
vector
detail
record
kept
time
genet
manipul
vector
well
document
verifi
sequenc
labgener
refer
standard
critic
raw
materi
biolog
ideal
larg
enough
stock
refer
standard
use
durat
develop
work
often
possibl
howev
produc
suffici
quantiti
materi
suffici
stabil
earli
develop
stage
reason
may
necessari
produc
fresh
batch
test
thoroughli
independ
standard
current
standard
standard
deplet
lose
potenc
consider
given
critic
reagent
cell
line
compound
obtain
outsid
sourc
refer
standard
key
reagent
made
obtain
adequ
amount
character
well
possibl
store
condit
maintain
stabil
least
durat
develop
process
improv
manufactur
assay
process
develop
improv
refer
standard
requir
quantiti
origin
standard
also
preserv
provid
materi
later
comparison
requir
case
retroviru
adenoviru
vector
develop
fda
made
avail
refer
materi
sponsor
standard
refer
reagent
avoid
futur
question
data
reliabl
investig
consid
outsourc
difficult
common
technolog
transmiss
electron
microscopi
tandem
liquid
chromatographi
mass
spectroscopi
peptid
map
dna
sequenc
adequ
facil
productspecif
assay
potenc
studi
pilot
anim
efficaci
toxic
studi
like
perform
best
research
facil
earli
develop
preclin
assay
protocol
develop
record
keep
must
ensur
data
use
later
ind
submiss
point
cgmp
process
develop
consider
given
technolog
transfer
critic
assay
glpcompliant
laboratori
prepar
support
repetit
studi
requir
cgmp
process
develop
manufactur
releas
postreleas
stabil
studi
durat
clinic
trial
toxicolog
materi
ideal
manufactur
use
process
use
manufactur
cgmp
clinic
materi
therefor
toxicolog
lot
produc
late
process
develop
concern
batchtobatch
variabl
product
singl
lot
toxicolog
initi
phase
trial
recommend
typic
toxicolog
lot
avail
sever
month
clinic
lot
readi
releas
studi
involv
autolog
cell
handl
cell
must
gmp
condit
preserv
steril
prevent
crosscontamin
cell
allogen
cell
import
use
cgmptest
cell
line
adequ
traceabl
includ
origin
passag
histori
exposur
media
product
may
deriv
anim
sourc
start
materi
must
routin
check
sequenc
accuraci
therefor
complet
plasmid
sequenc
also
prefer
examin
genet
stabil
lead
introduct
code
error
chang
protein
express
use
penicillinlik
antibiot
blactam
select
unaccept
possibl
allerg
reaction
patient
administ
product
produc
use
select
system
antibiot
kanamycin
substitut
altern
method
select
employ
measur
dna
qualiti
includ
supercoil
content
well
assay
endotoxin
genom
dna
contamin
product
system
indepth
guidanc
avail
guidanc
document
gener
recommend
fda
vector
smaller
kb
must
complet
sequenc
technolog
improv
criterion
may
well
expand
includ
larger
vector
genom
vector
genom
larger
kb
eg
herp
virus
poxvirus
must
transgen
sequenc
along
flank
region
signific
modif
vector
backbon
site
vulner
alter
molecular
manipul
qualifi
vaccin
strain
exist
vector
interest
eg
vaccinia
polioviru
prefer
cgmp
manufactur
deriv
investig
construct
use
vaccin
strain
avail
nih
atcc
commerci
sourc
adenoviru
vector
recent
avail
adenoviru
refer
standard
allow
normal
dose
base
viru
particl
concentr
infecti
unit
iu
titer
current
recommend
fda
ratio
viral
particl
infecti
unit
less
equal
replicationdefect
adenovirus
gener
replicationcompet
adenovirus
rca
must
measur
lot
produc
clinic
use
current
target
requir
fewer
rca
per
viru
particl
measur
cell
culturecytopath
effect
method
virus
replic
select
differ
test
strategi
eg
quantit
pcr
may
call
discuss
fda
similarli
agenc
may
special
consider
virus
alter
tropism
ensur
appropri
contain
prevent
gener
replicationcompet
adenoviru
expand
cell
tropism
note
rca
assay
must
optim
regard
presenc
defect
particl
factor
may
affect
sensit
assay
retrovirus
special
concern
possibl
insert
carcinogenesi
potenti
safeti
problem
amplifi
replicationcompet
retrovirus
rcr
gener
gener
guidelin
test
least
total
viru
vector
supernat
produc
amplifi
rcr
permiss
cell
line
addit
produc
cell
whichev
less
must
also
test
end
product
method
cocultur
permiss
cell
adenoviru
vector
retroviru
vector
tropism
modif
special
concern
may
requir
stringent
contain
patient
followup
promot
modif
may
also
affect
safeti
profil
viru
vector
lentivirus
gener
safeti
concern
retrovirus
particularli
replic
broader
varieti
cell
dormant
well
activ
divid
cell
although
retroviru
standard
avail
atcc
investig
develop
retroviru
vector
lentiviru
standard
current
offer
lentiviru
standard
plan
futur
primarili
great
variabl
lentiviru
backbon
current
develop
clinic
investig
eg
equin
murin
human
herp
virus
develop
clinic
use
either
must
replic
defect
replic
compet
must
shown
nonneurovirul
neurovirul
issu
polioviru
well
adenoassoci
viru
aav
vector
concern
although
vector
design
maintain
episom
revers
wild
type
result
integr
host
chromosom
vector
could
rescu
patient
concurr
adenoviru
infect
sever
interest
concept
seek
employ
modifi
bacteria
therapeut
agent
recombin
virus
gener
issu
safeti
well
specif
issu
genet
stabil
exchang
consid
stabil
new
genet
materi
may
requir
incorpor
bacteri
genom
rather
plasmid
lost
exchang
strategi
incorpor
new
genet
materi
bacteri
dna
depend
confirm
sequenc
accuraci
target
bacteri
sequenc
well
novel
genet
materi
introduct
antibiot
resist
gene
manufactur
step
rais
special
concern
avoid
use
altern
select
approach
whether
evalu
small
molecul
biolog
deriv
materi
gene
therapi
product
basic
intent
nonclin
toxic
studi
defin
pharmacolog
toxicolog
effect
predict
human
respons
prior
initi
phase
clinic
trial
human
also
throughout
entir
drug
develop
process
lead
ultim
biolog
licens
applic
bla
goal
studi
includ
first
defin
initi
safe
start
dose
dose
escal
scheme
firstinhuman
clinic
trial
second
identifi
potenti
target
organ
toxic
biomark
paramet
monitor
patient
receiv
therapi
determin
toxic
revers
final
determin
patient
popul
may
greater
risk
develop
toxic
given
cellular
gene
therapeut
product
nonclin
studi
design
follow
point
mind
whether
product
transduc
cell
popul
cell
administ
class
vector
use
appropri
anim
speci
physiolog
state
model
relev
clinic
indic
product
class
intend
dose
rout
administr
treatment
regimen
use
clinic
mani
question
need
taken
consider
address
design
phase
safeti
studi
includ
alreadi
known
like
toxic
relat
agent
biodistribut
local
well
system
toxic
immun
respons
immunogen
immunotox
potenti
insert
mutagenesi
biolog
activ
transgen
product
specif
question
aris
new
product
use
address
exampl
safeti
issu
primarili
relat
vector
transgen
product
method
administr
formulationexcipi
combin
might
exist
publish
unpublish
nonclin
clinic
data
address
question
mention
safeti
issu
address
studi
includ
evalu
toxic
vector
alon
irrespect
transgen
includ
potenti
toxic
andor
tumorigen
case
appar
previou
evalu
vector
toxic
transgen
express
vivo
may
evid
vitro
studi
occurr
consequ
ectop
transgen
express
nontarget
tissu
occurr
consequ
immun
respons
transgen
vector
protein
autoimmun
final
possibl
germlin
transduct
convent
pharmacolog
toxic
test
typic
use
evalu
small
molecul
may
alway
appropri
determin
safeti
biolog
activ
cellular
gene
therapi
product
issu
speci
specif
transduc
gene
permiss
infect
viral
vector
compar
anim
human
physiolog
consid
design
studi
avail
anim
model
mimick
diseas
indic
may
use
obtain
suffici
safeti
efficaci
data
prior
entri
agent
clinic
trial
earli
preind
discuss
fda
develop
toxicolog
plan
may
prevent
delay
ad
expens
inadequ
data
use
inappropri
speci
question
answer
preclin
pharmacologytoxicolog
studi
follow
relationship
dose
biolog
activ
relationship
dose
toxic
rout
andor
schedul
affect
activ
andor
toxic
risk
identifi
clinic
trial
ex
vivo
gene
transfer
product
consid
transduc
cell
gener
safeti
test
cfr
must
perform
final
product
appropri
modifi
procedur
may
develop
accord
cfr
fda
consid
propos
rule
make
amend
gener
safeti
test
rule
scope
applic
especi
cell
therapi
product
final
expect
nonclin
toxic
studi
conduct
complianc
glp
regul
howev
situat
highli
special
assay
requir
natur
biotechnologyderiv
product
possibl
conduct
assay
full
complianc
glp
eg
univers
discoveri
laboratori
import
area
identifi
impact
may
interpret
toxic
data
case
care
perform
studi
use
support
ind
bla
select
anim
model
use
variou
preclin
biodistribut
pharmacolog
toxicolog
studi
consider
given
scientif
rational
anim
speci
use
exampl
would
advantag
perform
studi
rodent
larger
number
anim
might
practic
necess
larg
anim
model
canin
nonhuman
primat
nonhuman
primat
studi
propos
clear
anoth
larg
anim
rodent
model
would
provid
inform
would
util
genet
defici
model
would
defici
model
relev
propos
studi
either
potenti
advers
immunolog
consequ
biolog
effect
defici
condit
anim
model
diseas
may
avail
everi
cellular
gene
therapi
system
propos
develop
make
speci
select
even
difficult
process
preclin
pharmacolog
safeti
test
agent
employ
appropri
pharmacolog
relev
anim
model
avail
relev
anim
speci
might
one
biolog
respons
therapi
mimic
human
respons
entail
knowledg
pathophysiolog
diseas
human
faith
reproduc
anim
model
speci
anim
chosen
preclin
toxic
evalu
viral
prepar
select
sensit
infect
product
patholog
sequela
induc
wildtyp
viru
relat
chosen
vector
well
util
model
biolog
activ
vector
construct
reason
expect
similar
distribut
receptor
permiss
anim
model
human
thu
speci
util
may
vari
vector
administ
transgen
express
rout
administr
patient
popul
treat
diseas
studi
rodent
model
rather
nonhuman
primat
may
use
suscept
patholog
induc
viru
class
eg
cotton
rat
semipermiss
host
adenoviru
infect
use
scid
mous
cotton
rat
may
suitabl
evalu
herp
simplex
viru
hsv
rather
aotu
monkey
investig
also
suggest
use
miniatur
swine
evalu
adenovir
vector
evalu
activ
vector
anim
model
clinic
indic
safeti
data
gather
model
assess
contribut
diseaserel
chang
physiolog
underli
patholog
respons
vector
special
circumst
illustr
point
follow
inbr
cotton
rat
sigmodon
hispidu
use
extens
anim
model
research
sinc
first
use
poliomyel
research
sinc
time
shown
semipermiss
host
adenovir
infect
studi
shown
pulmonari
lesion
replic
pattern
viru
seen
cotton
rat
parallel
seen
human
viru
persist
nasal
mucosa
lung
day
respect
inocul
even
presenc
hightit
neutral
antibodi
detect
day
although
cotton
rat
readili
adapt
laboratori
environ
retain
number
characterist
wild
counterpart
anim
tendenc
bite
panic
handl
jump
cage
larg
fightorflight
zone
care
handl
anim
describ
investig
cotton
rat
use
evalu
numer
adenoviru
vector
mani
rout
administr
studi
describ
earli
adenovir
vector
evalu
cotton
rat
discov
region
requir
replic
region
play
critic
role
pathogenesi
diseas
mutant
induc
markedli
greater
lymphocyt
macrophagemonocyt
inflammatori
respons
lung
replac
recombin
significantli
less
pathogen
virus
intranas
administr
studi
also
demonstr
adenoviru
replic
balbc
cba
mice
produc
result
similar
seen
cotton
rat
intracrani
administr
replicationdefect
adenoviru
express
herp
simplex
viru
thymidin
kinas
hsvtk
gene
dose
pfu
adenovir
immun
adenovir
cotton
rat
result
mild
gliosi
trace
mening
along
inject
tract
approxim
toxic
effect
dose
vector
administ
either
wistar
rat
rhesu
monkey
direct
neuron
injuri
doserel
inflammatori
respons
seen
inject
site
surround
parenchyma
appar
injuri
tissu
central
nervou
system
three
model
cerebr
spinal
fluid
blood
urin
stool
sampl
fail
cultur
adenoviru
studi
similar
hsvtk
adenoviru
inocul
cotton
rat
via
intracardiac
inject
dose
viral
particl
per
anim
without
ganciclovir
gcv
signific
microscop
lesion
observ
epicardi
inflamm
splenic
hemosiderosi
vector
sequenc
persist
throughout
assay
period
heart
lung
lymphoid
organ
infecti
virion
detect
hour
virion
detect
site
inject
two
anim
highest
dose
group
similar
vector
administ
either
one
two
subcutan
inject
cycl
viral
particleskg
singl
cours
viral
particleskg
signific
treatmentrel
histopatholog
find
dermat
mild
acanthosi
site
vector
inject
addit
local
effect
mild
hyperamylasemia
lymphocytosi
granulocytosi
seen
clinic
clinic
sign
toxic
death
observ
vector
sequenc
detect
skin
inject
site
lesser
extent
liver
spleen
lung
small
amount
vector
dna
detect
ovari
clear
rapidli
absenc
viral
sequenc
excreta
swab
major
anim
suggest
signific
replic
adenoviru
vector
host
littl
shed
owl
monkey
aotu
trivirgatu
nancyma
excel
model
oncogen
nononcogen
virus
hsv
type
other
herp
viru
infect
anim
strain
anim
routin
use
test
vaccin
found
mimic
cours
diseas
human
result
natur
anim
use
evalu
safeti
gene
therapi
vector
produc
howev
anim
tend
fragil
use
speci
result
must
handl
greater
care
attenu
replicationcompet
recombin
test
safeti
intracerebr
inocul
aotu
anim
receiv
dose
either
pfu
pfu
wildtyp
strain
f
wildtyp
caus
rapid
mortal
symptom
consist
hsv
enceph
includ
fever
hemiparesi
mening
hemorrhag
basal
ganglia
year
inocul
seven
treat
anim
aliv
exhibit
evid
clinic
complic
indic
form
hsv
consider
attenu
comparison
wildtyp
viru
two
anim
reinocul
pfu
stereotact
coordin
year
initi
dose
anim
aliv
healthi
year
second
inocul
comprehens
clinic
evalu
anim
subject
cerebr
magnet
reson
imag
mri
studi
inocul
studi
fail
reveal
radiograph
evid
typic
hsvrelat
sequela
brain
seen
anim
treat
wildtyp
viru
microscop
examin
multipl
tissu
found
evid
hsvinduc
histopatholog
dissemin
spite
fact
measur
increas
serum
antihsv
titer
detect
viral
shed
biodistribut
aotu
also
evalu
use
pcr
analys
viral
cultur
tear
saliva
vagin
secret
sampl
neither
infecti
viru
viral
dna
detect
timepoint
month
postinocul
analys
tissu
obtain
necropsi
month
year
inocul
show
distribut
dna
restrict
brain
although
infecti
viru
isol
sampl
safeti
construct
also
evalu
aotu
intraprostat
inject
safeti
assess
basi
clinic
observ
viral
biodistribut
viru
shed
histopatholog
none
inject
monkey
display
evid
clinic
diseas
shed
infecti
viru
spread
viru
organ
signific
microscop
abnorm
observ
organ
evalu
result
studi
demonstr
safe
inocul
either
brain
prostat
aotu
monkey
could
success
use
preclin
toxicolog
evalu
addit
studi
perform
vector
aotu
monkey
balbc
mice
also
use
evalu
safeti
mice
inocul
manner
aotu
either
intracerebr
intraventricularli
pfu
surviv
week
appar
symptom
diseas
contrast
anim
inocul
intracerebr
pfu
wildtyp
strain
ko
anim
inocul
intraventricularli
pfu
wildtyp
strain
f
die
within
day
mice
inocul
intrahepat
pfu
anim
surviv
week
wherea
anim
surviv
even
week
inocul
pfu
wildtyp
ko
mice
also
inject
prostat
either
wildtyp
strain
f
observ
month
none
anim
exhibit
clinic
sign
diseas
die
howev
mice
inject
strain
f
display
sluggish
hunch
behavior
dead
day
microscop
examin
prostat
inject
normal
wherea
inject
strain
f
show
epitheli
flatten
slough
stromal
edema
studi
describ
whitley
scid
mous
point
fact
rodent
use
place
owl
monkey
produc
adequ
safeti
data
evalu
vector
gene
therapi
final
safeti
data
also
obtain
welldesign
efficaci
studi
mani
case
mous
studi
provid
similar
inform
studi
conduct
nonhuman
primat
smaller
speci
automat
reject
nonhuman
primat
reli
use
model
simpli
comfort
go
studi
human
evalu
toxic
agent
nonhuman
primat
experi
repeatedli
shown
numer
class
agent
small
molecul
well
biolog
one
speci
may
predict
human
toxic
human
toxic
may
seen
anim
speci
final
certain
human
popul
may
predict
human
popul
last
fact
make
predict
everi
toxic
almost
imposs
dose
vector
use
nonclin
studi
select
base
preliminari
efficaci
activ
data
vitro
vivo
studi
noeffect
dose
level
overtli
toxic
dose
sever
intermedi
dose
evalu
along
appropri
control
vehicletr
anim
new
formul
import
includ
last
group
distinguish
formulationrel
effect
agent
interest
product
difficult
produc
larg
quantiti
result
limit
suppli
product
inher
low
toxic
maximum
toler
dose
may
achiev
result
maximum
feasibl
dose
may
administ
highest
level
test
preclin
studi
design
appropri
report
although
may
intellectu
scientif
satisfi
data
deriv
studi
least
establish
safeti
clinic
start
dose
preclin
safeti
toxic
studi
includ
least
one
dose
equival
least
one
dose
escal
level
exceed
propos
clinic
trial
multipl
human
dose
requir
determin
adequ
safeti
margin
may
vari
class
vector
employ
relev
anim
model
human
rational
dose
select
provid
scale
dose
base
either
bodi
weight
total
bodi
surfac
area
appropri
facilit
comparison
across
anim
speci
use
human
although
small
molecul
cancer
therapeut
scale
base
bodi
surfac
area
bodi
surfac
area
may
appropri
gene
therapeut
inform
gener
preclin
studi
use
determin
margin
safeti
vector
use
clinic
trial
well
gage
accept
dose
escal
scheme
depend
steep
toxic
curv
cross
comparison
dose
adenovir
vector
cystic
fibrosi
similar
toxic
seen
cotton
rat
mice
hamster
rhesu
monkey
baboon
agent
directli
instil
lung
anim
dose
scale
bodi
surfac
area
observ
advers
effect
level
variou
speci
remark
similar
one
anoth
first
human
dose
toxic
observ
ium
vs
ium
human
notabl
except
rhesu
monkey
ium
studi
like
enabl
investig
make
wiser
choic
select
dose
speci
evalu
rout
administr
vector
obviou
influenc
toxic
vivo
distribut
concentr
agent
produc
exampl
intraven
bolu
dose
produc
high
concentr
short
durat
rout
administr
subcutan
may
produc
much
lower
concentr
prolong
exposur
current
practic
recommend
safeti
evalu
preclin
studi
conduct
ident
rout
method
administr
propos
phase
clinic
trial
whenev
possibl
difficult
achiev
small
anim
speci
method
administr
similar
plan
use
clinic
advis
exampl
intrapulmonari
instil
adenovir
vector
intranas
administr
cotton
rat
mice
accept
altern
direct
intrapulmonari
administr
bronchoscop
latter
procedur
simpli
feasibl
rodent
propos
clinic
rout
nonintraven
eg
intratumor
may
wise
also
conduct
intraven
studi
provid
perhap
worsecas
data
may
happen
event
accident
inject
directli
patient
blood
vessel
possibl
schedul
administr
anim
studi
also
ident
intend
phase
clinic
trial
may
feasibl
certain
instanc
product
neutral
antibodi
anim
model
might
preclud
repeat
administr
may
factor
human
studi
addit
agent
administ
combin
gene
therapi
agent
eg
suicid
therapi
use
hsvtk
gcv
hsv
cytosin
deaminas
rout
schedul
also
ident
plan
clinic
evalu
vector
alon
anim
model
would
provid
suffici
data
predict
addit
toxic
may
produc
combin
least
one
arm
plan
preclin
anim
studi
minimum
treat
anim
monitor
gener
health
statu
clinic
observ
bodi
weight
temperatur
chang
chang
food
water
consumpt
serum
biochemistri
hematolog
profil
target
organ
critic
tissu
examin
gross
microscop
chang
addit
paramet
evalu
depend
natur
product
studi
speci
use
rout
administr
set
allinclus
paramet
suffici
everi
new
agent
studi
design
specif
agent
util
appropri
test
captur
much
relev
data
possibl
mani
biotechnologyderiv
pharmaceut
intend
human
use
immunogen
anim
use
animalderiv
proteinsproduct
avail
consid
defin
intrins
toxic
new
agent
may
entail
parallel
develop
process
construct
relev
speci
safeti
test
develop
point
allow
relev
safeti
test
proceed
analog
human
construct
may
actual
brought
clinic
support
result
human
materi
use
measur
antibodi
associ
administr
product
alway
perform
conduct
repeat
dose
toxic
studi
data
assist
investig
interpret
result
studi
antibodi
respons
produc
anim
fulli
character
eg
titer
number
respond
anim
neutral
nonneutr
appear
correl
pharmacolog
andor
toxicolog
chang
observ
specif
effect
antibodi
format
pharmacokinet
andor
pharmacodynam
incid
andor
sever
advers
effect
complement
activ
emerg
new
toxic
effect
consid
interpret
data
attent
also
paid
evalu
possibl
patholog
chang
relat
immun
complex
format
deposit
especi
kidney
treat
anim
detect
antibodi
anim
sole
criterion
earli
termin
preclin
safeti
studi
modif
durat
studi
unless
immun
respons
neutral
pharmacolog
andor
toxicolog
effect
biopharmaceut
larg
proport
anim
case
immun
respons
biopharmaceut
anim
variabl
similar
respons
human
issu
compromis
interpret
data
safeti
studi
special
signific
ascrib
antibodi
respons
induct
antibodi
format
anim
necessarili
predict
potenti
antibodi
format
human
token
human
may
also
develop
serum
antibodi
human
protein
frequent
therapeut
respons
persist
presenc
may
happen
anim
purifi
protein
administ
via
gene
therapi
viral
vector
case
human
factor
ix
purifi
protein
administ
rhesu
macaqu
monkey
make
antibodi
howev
factor
ix
administ
firstgener
adenovir
vector
anim
mount
acut
phase
respons
produc
neutral
antibodi
elimin
factor
ix
circul
final
occurr
sever
anaphylact
respons
recombin
protein
rare
human
result
guinea
pig
anaphylaxi
test
gener
posit
protein
product
consid
predict
reaction
human
therefor
studi
consid
littl
valu
routin
evalu
type
product
even
though
frequent
perform
inflammatori
immun
autoimmun
respons
induc
gene
product
may
concern
anim
studi
conduct
suffici
durat
time
allow
develop
respons
host
immun
respons
viral
transgen
protein
may
limit
use
repeat
administr
clinic
immun
statu
intend
recipi
gene
therapi
consid
riskbenefit
analysi
product
particularli
viral
vector
exclus
immunocompromis
patient
would
unduli
restrict
clinic
protocol
immunesuppress
genet
immunodefici
newborn
anim
may
use
preclin
studi
evalu
potenti
safeti
risk
extrem
import
investig
potenti
undesir
pharmacolog
activ
appropri
anim
model
necessari
incorpor
particular
monitor
activ
nonclin
toxic
studi
andor
clinic
studi
safeti
pharmacolog
studi
design
measur
function
indic
potenti
toxic
indic
may
investig
separ
studi
may
care
incorpor
design
nonclin
toxic
studi
aim
studi
reveal
function
effect
major
physiolog
system
bodi
eg
cardiovascular
respiratori
renal
central
nervou
system
major
impact
whether
agent
administ
clinic
investig
may
includ
use
isol
organ
test
system
involv
use
intact
anim
use
perfus
rabbit
heart
model
evalu
torsad
de
point
qt
prolong
result
safeti
pharmacolog
studi
may
allow
mechanist
base
explan
specif
organ
toxic
consid
care
respect
human
use
intend
indic
use
addit
biomark
exemplifi
cardiac
troponin
agent
potenti
cardiac
toxic
may
warrant
addit
nonclin
anim
studi
andor
clinic
studi
human
pharmacolog
studi
divid
three
main
categori
depend
natur
effect
primari
secondari
pharmacodynam
studi
safeti
pharmacolog
studi
safeti
pharmacolog
studi
defin
ich
guidanc
document
subject
studi
investig
potenti
undesir
pharmacodynam
effect
substanc
physiolog
function
relat
exposur
therapeut
rang
last
point
particularli
import
studi
conduct
dose
level
serum
concentr
therapeut
target
base
prior
efficacyact
studi
simpli
conduct
studi
low
dose
provid
much
use
inform
adequ
assess
safeti
agent
object
studi
identifi
undesir
pharmacodynam
properti
drug
substanc
may
relev
human
safeti
toxic
evalu
fulli
advers
pharmacodynam
andor
pathophysiolog
effect
drug
substanc
previous
observ
nonclin
toxicolog
andor
clinic
studi
investig
mechan
action
advers
pharmacodynam
effect
either
previous
observ
suspect
investig
plan
develop
meet
object
clearli
identifi
delin
drug
develop
team
biotechnologyderiv
product
achiev
highli
specif
receptor
target
often
suffici
evalu
safeti
pharmacolog
endpoint
part
welldesign
toxicolog
andor
pharmacodynam
studi
therefor
need
separ
safeti
pharmacolog
studi
reduc
elimin
bioproduct
repres
new
therapeut
class
andor
product
achiev
highli
specif
receptor
target
extens
evalu
separ
safeti
pharmacolog
studi
consid
biodistribut
studi
gener
perform
gene
therapi
product
typic
pharmacokinet
studi
use
type
drug
measur
serum
plasma
level
halflif
clearanc
like
gener
perform
preclin
anim
biodistribut
studi
design
determin
distribut
vector
site
intend
therapeut
site
indic
potenti
toxic
goal
studi
gener
twofold
determin
dissemin
vector
germlin
distribut
vector
nontarget
tissu
first
routin
accomplish
assay
total
gonad
tissu
second
provid
inform
potenti
target
organ
toxic
may
address
preclin
studi
studi
may
use
normal
intact
anim
anim
model
diseas
latter
studi
may
repres
clinic
set
whenev
possibl
intend
rout
administr
employ
consider
group
anim
might
also
treat
intraven
worstcas
scenario
transfer
gene
normal
surround
distal
tissu
well
target
site
evalu
use
sensit
detect
method
possibl
revers
transcriptas
pcr
includ
evalu
gene
persist
aberr
unexpect
local
observ
addit
studi
conduct
determin
whether
gene
express
whether
presenc
associ
patholog
effect
biodistribut
studi
may
necessari
new
agent
previous
defin
vector
previou
experi
similar
vector
rout
administr
formul
schedul
eg
adenoviru
type
vector
transgen
product
consid
innocu
express
ectop
size
new
vector
essenti
differ
biodistribut
aspect
prior
agent
may
referenc
hand
studi
may
postpon
new
class
vector
use
ie
littl
previou
experi
eg
aav
lentiviru
other
chang
formul
ie
lipid
carrier
instead
aqueou
formul
rout
administr
chang
intent
system
rout
local
administr
establish
vector
final
transgen
potenti
induc
toxic
aberrantli
express
nontarget
organ
toxic
studi
number
factor
taken
consider
design
vector
biodistribut
studi
regard
speci
select
nonhuman
primat
alway
need
rodent
may
perfectli
accept
anim
gender
reflect
intend
patient
popul
least
anim
per
sex
group
use
minimum
use
smaller
anim
ie
mice
rat
allow
inclus
larger
number
anim
easi
evalu
time
point
studi
follow
dose
group
includ
practic
control
maxim
feasibleclin
relev
dose
lower
dose
establish
observ
advers
effect
level
rout
administr
mimic
intend
clinic
rout
greatest
extent
possibl
regard
anim
sacrific
andor
sampl
time
point
earli
point
reflect
peak
vector
transductionexpress
includ
later
timepoint
determin
intend
clinic
use
timepoint
reflect
clearanc
gonad
nontarget
organ
determin
persist
follow
tissu
gener
recommend
peripher
blood
gonad
inject
site
highli
perfus
organ
assist
determin
toxic
brain
liver
lung
kidney
heart
spleen
tissu
base
toxicitypatholog
determin
transgen
eg
bone
marrow
base
rout
administr
drain
contralater
lymph
node
methodolog
use
detect
agent
detect
sequenc
vector
dna
ribonucl
acid
uniqu
product
appropri
detect
vector
sequenc
adequ
tissu
sampl
preclin
anim
studi
sampl
obtain
initi
clinic
trial
mani
point
present
discuss
section
elabor
publicli
access
fda
document
shed
viral
vector
skin
excreta
obviou
concern
highli
infecti
virus
measur
dissemin
persist
shed
vector
multipl
tissu
eg
brain
heart
lung
spleen
liver
kidney
ovari
skin
well
bodili
fluid
urin
fece
tear
saliva
vagin
secret
skin
swab
taken
multipl
timepoint
throughout
studi
analyz
realtim
quantit
pcr
presenc
vector
sequenc
vector
sequenc
rapidli
clear
viral
sequenc
absent
excreta
swab
major
anim
suggest
signific
replic
vector
host
even
intend
clinic
schedul
involv
repeat
dose
singledos
studi
may
gener
use
data
describ
relationship
dose
system
andor
local
toxic
steep
dosetox
curv
data
studi
use
select
dose
repeateddos
toxic
studi
inform
doserespons
relationship
may
gather
conduct
singledos
toxic
studi
compon
pharmacolog
anim
model
efficaci
studi
incorpor
safeti
pharmacolog
paramet
design
studi
consid
reduc
number
anim
use
amount
product
requir
number
studi
must
perform
rout
dose
regimen
studi
eg
daili
vs
intermitt
dose
reflect
intend
clinic
use
exposur
eg
week
week
everi
day
etc
recoveri
period
includ
determin
revers
potenti
worsen
pharmacolog
toxicolog
effect
andor
potenti
delay
toxic
effect
biopharmaceut
induc
prolong
pharmacologicaltoxicolog
effect
recoveri
group
anim
monitor
revers
demonstr
may
fundament
obviou
outset
studi
durat
repeat
dose
studi
base
intend
durat
clinic
exposur
diseas
indic
durat
anim
dose
gener
month
biotechnologyderiv
pharmaceut
probabl
case
gene
therapi
studi
howev
case
lifethreaten
diseas
cancer
longer
term
studi
gener
requir
support
phase
trial
one
aspect
immunotoxicolog
evalu
includ
assess
potenti
immunogen
describ
section
mani
biotechnologyderiv
pharmaceut
intend
stimul
suppress
immun
system
therefor
may
affect
humor
also
cellmedi
immun
inflammatori
reaction
inject
site
may
indic
stimulatori
respons
import
howev
recogn
simpl
inject
trauma
specif
toxic
effect
caus
formul
vehicl
may
also
result
toxic
chang
inject
site
addit
express
surfac
antigen
target
cell
may
alter
implic
autoimmun
potenti
convent
small
molecul
drug
reproduct
toxic
usual
assess
rat
rabbit
speci
specif
potenti
immunogen
biolog
led
increas
use
nonhuman
primat
purpos
need
reproduct
development
toxic
studi
depend
product
clinic
indic
intend
patient
popul
specif
studi
design
dose
schedul
may
modifi
base
issu
relat
speci
specif
immunogen
biolog
activ
andor
long
elimin
halflif
issu
germlin
integr
prompt
consider
public
discuss
gene
therapi
product
directli
administ
patient
risk
vector
transfer
germ
cell
serious
consid
anim
testicular
ovarian
sampl
analyz
vector
sequenc
sensit
method
avail
signal
detect
gonad
studi
conduct
determin
sequenc
present
germ
cell
oppos
stromal
tissu
techniqu
use
may
includ
limit
cell
separ
situ
pcr
techniqu
semen
sampl
analysi
collect
matur
anim
includ
mice
wellestablish
method
determin
vector
incorpor
germ
cell
evalu
biodistribut
gonad
may
need
prior
phase
clinic
trial
issu
consid
care
preind
meet
fda
inform
consent
form
address
lack
data
unknown
risk
genotox
studi
ame
salmonella
assay
micronucleu
test
mous
lymphoma
assay
routin
conduct
small
molecul
pharmaceut
applic
biotechnologyderiv
pharmaceut
especi
gene
therapi
product
therefor
need
administr
larg
quantiti
peptid
protein
virus
may
yield
uninterpret
result
caus
concern
product
genotox
studi
perform
avail
relev
system
includ
newli
develop
system
use
standard
genotox
studi
indic
assess
genotox
potenti
process
contamin
consid
appropri
standard
assay
perform
purpos
rational
provid
standard
carcinogen
bioassay
normal
mice
rat
gener
inappropri
biotechnologyderiv
pharmaceut
probabl
gene
therapi
product
issu
receiv
addit
attent
owe
emerg
lymphoprolif
syndrom
potenti
signific
fraction
recipi
vector
design
treat
scid
syndrom
clinic
result
actual
recapitul
certain
degre
toxic
anticip
experi
anim
model
thu
productspecif
assess
carcinogen
potenti
still
need
biopharmaceut
studi
util
must
refin
consider
durat
anticip
clinic
dose
patient
popul
biolog
activ
product
eg
retroviru
vector
growth
factor
immunosuppress
agent
etc
concern
carcinogen
potenti
varieti
new
approach
may
consid
evalu
risk
potenti
support
induc
prolifer
transform
cell
clonal
expans
lead
neoplasia
consid
possibl
product
evalu
respect
receptor
express
biopharmaceut
transgen
express
form
variou
malign
normal
human
cell
especi
potenti
relev
patient
popul
studi
abil
biopharmaceut
stimul
growth
normal
andor
malign
cell
express
relev
receptor
determin
vitro
studi
give
caus
concern
carcinogen
potenti
studi
relev
anim
model
may
need
avail
relev
state
section
gene
transfer
agent
must
evalu
standard
rodent
model
mice
rat
carcinogen
bioassay
probabl
appropri
daili
administr
vector
usual
perform
studi
feasibl
howev
sever
vector
includ
aav
continu
express
lifetim
anim
factor
may
limit
host
immun
respons
vector
transgen
may
either
limit
toxic
perhap
develop
neutral
antibodi
may
effect
tumor
develop
necessari
consult
fda
develop
productspecif
studi
individu
basi
determin
whether
carcinogen
studi
need
local
toler
administr
new
agent
evalu
formul
intend
clinic
trial
test
unless
cogent
reason
would
feasibl
biolog
meaning
case
potenti
advers
effect
product
site
administr
evalu
singleor
repeateddos
toxic
studi
usual
conduct
normal
cours
develop
thu
elimin
need
separ
studi
adenovir
vector
effici
deliv
gene
wide
varieti
divid
nondivid
cell
type
vitro
vivo
result
high
level
transient
gene
express
consider
modif
made
wildtyp
viru
reduc
infect
toxic
normal
tissu
improv
transduct
tropism
tumor
cell
death
jess
gelsing
sever
complic
includ
liver
failur
coupl
fact
adenoviru
infect
immunocompromis
oncolog
patient
lead
fatal
hepatotox
report
seriou
hepatotox
death
nonhuman
primat
treat
differ
adenovir
vector
make
safeti
evalu
vector
cancer
treatment
paramount
firstgener
adenoviru
vector
express
human
factor
ix
intraven
inject
rhesu
macaqu
dose
pfukg
toxic
seen
lower
dose
level
substanti
doselimit
liver
toxic
observ
higher
dose
hepatotox
manifest
elev
serum
transaminas
level
hyperbilirubinemia
hypoalbuminemia
prolong
clot
time
evid
liver
toxic
resolv
except
persist
hypofibrinogenemia
highdos
recipi
indic
possibl
perman
liver
damag
data
suggest
narrow
therapeut
window
firstgener
adenovirusmedi
gene
transfer
vector
followup
studi
conclud
abnorm
may
caus
direct
toxic
effect
adenoviru
vector
may
result
indirectli
accompani
acut
inflammatori
respons
mark
elev
interleukin
anoth
firstgener
adenovir
vector
express
bgalactosidas
intraven
inject
two
baboon
dose
particleskg
baboon
receiv
high
dose
develop
acut
symptom
decreas
platelet
count
increas
liver
enzym
becam
moribund
hour
inject
baboon
receiv
lower
dose
develop
symptom
narrow
therapeut
index
demonstr
recombin
adenovirus
infus
portal
vein
adult
rhesu
monkey
dose
particleskg
result
format
neutral
antibodi
sever
liver
toxic
death
readministr
second
vector
associ
degre
toxic
first
vector
prompt
much
vigor
neutral
antibodi
respons
administr
sever
gene
transfer
vehicl
rout
studi
rhesu
monkey
develop
model
adenovirusmedi
gene
transfer
liver
vector
administ
via
portal
vein
saphen
vein
effici
result
transient
gene
express
accompani
immun
respons
vector
transgen
product
acut
hepat
turn
model
intracerebr
administr
baboon
receiv
intracerebr
inject
either
high
dose
replicationdefect
adenovir
vector
express
hsvtk
pfu
without
gcv
low
dose
advrsvtk
pfu
gcv
evalu
safeti
regimen
anim
receiv
highdos
vector
gcv
either
die
becam
moribund
sacrif
first
day
treatment
necropsi
anim
reveal
caviti
coagul
necrosi
inject
site
anim
receiv
highdos
vector
clinic
normal
howev
lesion
detect
mri
inject
site
correspond
cystic
caviti
necropsi
anim
receiv
lowdos
vector
gcv
clinic
normal
exhibit
small
mri
abnorm
although
gross
lesion
present
necropsi
microscop
foci
necrosi
present
neutral
antibodi
produc
anim
shed
vector
found
urin
fece
serum
day
intracerebr
inject
intrapulmonari
administr
use
exemplifi
use
recombin
adenoviru
vector
contain
express
cassett
human
cystic
fibrosi
transmembran
conduct
regul
instil
bronchoscop
limit
region
lung
baboon
advers
effect
note
mononuclear
cell
inflammatori
respons
within
alveolar
compart
anim
receiv
dose
viru
requir
induc
detect
gene
express
minim
inflamm
seen
pfuml
promin
pfuml
perivascular
lymphocyt
histiocyt
infiltr
seen
host
immun
elimin
infect
cell
often
limit
gene
express
vivo
week
infect
addit
cellmedi
immun
respons
adenoviru
infect
humor
respons
inject
viru
often
gener
although
humor
respons
may
prevent
use
adenovir
vector
repeat
dose
may
block
reduc
coadministr
immunosuppress
agent
cytokin
altern
use
adenovirus
differ
serotyp
may
allow
repeat
administr
even
presenc
neutral
antibodi
harvey
et
al
report
year
experi
local
administr
low
particl
unit
intermedi
particl
unit
dose
vector
six
differ
site
group
incid
major
advers
event
death
relat
administr
adenoviru
vector
local
administr
low
intermedi
dose
adenoviru
vector
well
toler
secondgener
adenovir
vector
mutat
propos
decreas
host
immun
respons
transduc
cell
reduc
toxic
increas
durat
express
compar
firstgener
vector
delet
safeti
adenovir
vector
encod
epitopetag
bdomaindelet
human
factor
viii
complementari
dna
evalu
cynomolgu
monkey
anim
receiv
intraven
administr
either
particleskg
vector
distribut
widespread
highest
level
observ
liver
spleen
histopatholog
hematolog
serum
chemistri
analysi
identifi
liver
blood
major
site
toxic
transient
mild
serum
elev
liver
enzym
observ
along
dosedepend
inflammatori
respons
liver
addit
mild
lymphoid
hyperplasia
observ
spleen
mild
anemia
transient
decreas
platelet
count
observ
marrow
hyperplasia
extramedullari
hematopoiesi
vector
delet
contain
either
temperaturesensit
mutat
gene
delet
region
infus
hepat
arteri
nonhuman
primat
minim
toxic
seen
histopatholog
show
portal
inflamm
present
throughout
liver
anim
receiv
high
dose
differ
seen
level
portal
inflamm
target
untarget
lobe
pcr
analysi
detect
viral
dna
sequenc
gonad
brain
well
mani
tissu
baboon
treat
highdos
vector
baboon
treat
lower
dose
vector
express
human
ornithin
transcarbamylas
gene
dna
detect
nest
pcr
liver
gonad
day
data
suggest
intraarteri
administr
recombin
adenovir
vector
feasibl
safe
toxic
firstgener
vector
express
human
evalu
mice
administr
increas
dose
start
particleskg
vector
induc
dosedepend
toxic
includ
transient
thrombocytopenia
elev
alanin
aminotransferas
increas
hepatocyt
prolifer
follow
inflamm
hypertrophi
differ
toxic
two
vector
measur
match
level
human
express
howev
vector
slightli
reduc
hepatocyt
toxic
intermedi
particl
dose
although
vector
purport
less
toxic
fact
remain
human
fatal
occur
ornithin
transcarbamylas
defici
trial
univers
pennsylvania
construct
current
adenovirus
infect
wide
varieti
cell
specif
interact
viral
fiber
protein
least
one
cell
surfac
receptor
entri
viru
cell
enhanc
specif
interact
fiber
integrin
coreceptor
host
rang
tissu
suscept
viru
therefor
alter
variou
strategi
bind
effici
target
cell
surfac
antibodi
tissuespecif
cell
surfac
protein
also
coupl
fiber
protein
facilit
partial
target
viru
anoth
approach
achiev
target
viru
use
cellspecif
promot
drive
express
therapeut
gene
context
recombin
viru
enhanc
uptak
strategi
fiber
modif
may
present
special
concern
toxic
especi
regard
hepatotox
administ
intraven
direct
hepat
arteri
inject
care
comparison
tropismmodifi
adenovir
vector
nontropismmodifi
vector
mous
toxic
biodistribut
studi
well
nonhuman
primat
toxic
studi
might
desir
member
famili
parvovirida
aav
among
smallest
dna
virus
unlik
autonom
parvovirus
aav
dependovirus
requir
coinfect
unrel
helper
virus
product
infect
occur
recombin
vector
gene
therapi
seem
sever
advantag
compar
vector
transduct
termin
differenti
nondivid
cell
rel
high
stabil
transgen
express
potenti
target
integr
safeti
point
view
aav
vector
show
lack
pathogen
low
immunogen
low
risk
insert
mutagenesi
also
appear
evid
transduct
gonad
rhesu
monkey
howev
aav
limit
dna
capac
hsv
vector
deliv
larg
amount
exogen
dna
howev
cytotox
mainten
transgen
express
obviou
obstacl
use
also
advantag
abil
infect
nondivid
cell
establish
latenc
cell
type
abil
establish
latenc
neuron
cell
make
hsv
attract
vector
treat
neurolog
disord
parkinson
alzheim
diseas
addit
abil
hsv
infect
effici
number
differ
cell
type
muscl
liver
may
make
excel
vector
treat
nonneurolog
diseas
one
problem
associ
hsvbase
vector
toxic
vector
mani
differ
cell
type
gener
hsv
vector
delet
mani
immedi
earli
gene
product
similar
strategi
use
adenoviru
result
vector
reduc
toxic
antigen
well
prolong
express
vivo
clinic
studi
report
detail
vector
section
detail
summari
preclin
safeti
consider
pertain
use
aotu
monkey
comparison
rodent
speci
retroviru
vector
replicationdefect
primarili
base
moloney
murin
leukemia
viru
mmlv
wellstudi
wellcharacter
retroviru
numer
advantag
extens
studi
produc
stabl
integr
host
genom
effici
gene
transfer
disadvantag
includ
infect
limit
divid
cell
make
gene
transfer
nondivid
cell
hematopoiet
stem
cell
hepatocyt
myoblast
neuron
imposs
low
titer
product
four
theoret
concern
exist
retroviralmedi
gene
transfer
relat
two
potenti
delay
toxic
insert
mutagenesi
recombin
endogen
retrovir
sequenc
transfer
exogen
genet
materi
accident
exposur
replicationcompet
murin
retrovirus
retrovir
vector
perman
integr
genom
infect
cell
seriou
concern
regard
insert
mutagenesi
caus
develop
secondari
malign
presenc
rcr
major
concern
fact
rcr
produc
lethal
malign
tcell
lymphoma
rhesu
monkey
concern
result
public
concern
fda
consider
issu
issuanc
new
fda
guidanc
subject
octob
concern
longer
theoret
elat
type
retroviralmedi
therapi
success
cure
number
children
scid
sever
dampen
report
leukemialik
diseas
produc
two
children
unlik
oncoretrovirusu
moloney
murin
leukemia
viru
one
subclass
retrovirus
lentivirus
infect
nondivid
cell
make
virus
attract
gene
transfer
one
virus
human
immunodefici
viru
hiv
subject
investig
number
group
obviou
concern
use
hiv
gene
therapi
safeti
possibl
gener
replicationcompet
viru
vector
product
involv
engin
vector
replic
defect
done
number
case
elimin
accessori
gene
tat
vif
vpr
vpu
nef
packag
construct
still
abil
transduc
cell
concern
possibl
insert
activ
cellular
oncogen
random
integr
vector
proviru
host
genom
led
develop
selfinactiv
vector
use
selfinactiv
virus
significantli
improv
biosafeti
hivderiv
vector
reduc
likelihood
rcr
origin
vector
product
target
cell
hamper
recombin
wildtyp
hiv
infect
host
attempt
make
even
safer
construct
group
work
develop
lentivir
vector
simian
immunodefici
viru
bovin
immunodefici
viru
felin
immunodefici
viru
last
vector
may
inher
accept
base
none
newer
construct
move
toward
clinic
littl
anim
safeti
data
human
data
vector
yet
chapter
present
rang
issu
might
consid
contempl
develop
gene
therapi
agent
point
earli
phase
clinic
trial
gene
therapi
product
yet
recogn
safe
effect
standard
approach
issu
regard
much
work
progress
inde
natur
agent
would
suggest
new
opportun
would
call
uniqu
set
requir
singl
approach
probabl
never
standardli
exist
rather
principl
underli
regulatori
polici
woven
approach
new
agent
broad
stroke
involv
approach
answer
follow
question
ident
agent
clearli
defin
success
batch
materi
made
reproduc
quantiti
support
clinic
develop
known
biolog
featur
vector
transgen
applic
clearli
similar
anim
speci
use
safeti
studi
human
least
far
ascertain
dose
like
requir
therapeut
effect
level
gene
express
replic
necessari
attain
therapeut
effect
toxic
occur
agent
evid
toxic
revers
toxic
repeat
dose
agent
like
attenu
magnifi
immunolog
respons
agent
consequ
longterm
presenc
therapeut
agent
recipi
danger
produc
directli
therapeut
agent
indirectli
recombin
andor
replic
infecti
agent
act
horizont
popul
vertic
across
gener
presenc
distribut
gene
therapi
agent
follow
patient
sponsor
encourag
see
regulatori
process
collabor
interact
regulatori
agenc
end
protect
patient
also
advanc
scientif
defens
rigor
question
clinic
trial
far
costli
conduct
experi
design
compliant
regulatori
requir
fail
overtli
injuri
clinic
trial
clear
understand
proactiv
approach
address
regulatori
issu
outlin
maxim
ensur
likelihood
interpret
clinic
outcom
regulatori
issu
outlin
must
approach
continu
appreci
evolv
scienc
associ
gene
therapi
field
requir
may
evolv
state
scienc
care
sustain
contact
regulatori
agenc
import
incorpor
best
current
scienc
design
conduct
interpret
regulatori
studi
